AKTX

Akari Therapeutics plc ADS

$7.28

Current Price

All

AI analysis

Read what the AI thinks of Akari Therapeutics plc ADS in the app.

Analyses are generated by AI from public data and are not investment advice.

Get the app

Key figures

Dividend per share

—

Yield

—

EPS

-$0.00

P/E

—

Data as of Oct 1

Why it matters for the long term

Over 10-20 years, what drives a share up is the growth of its profits (EPS) + reinvested dividends. The P/E tells you whether you are paying a lot or a little for that growth. In short: rising EPS + reasonable P/E + growing dividend = good long-term candidate.

Upcoming events

Quarterly earnings

Expected EPS: -$2.13

Nov 11

Posts

No posts about AKTX yet.

About Akari Therapeutics plc ADS

AKTX is a US biotechnology company, which means it develops experimental medicines and has no approved products to sell yet. It earns no revenue today. It pays its bills by selling shares to investors and drawing on cash reserves. Our data has no detailed company description, so the specific drug programs are not covered here.